How Common Are Polivy's Side Effects?
Polivy (polatuzumab vedotin), used with bendamustine and rituximab for relapsed or refractory diffuse large B-cell lymphoma, has side effects that occur frequently in clinical trials. In the pivotal GO29365 trial, over 80% of patients experienced any adverse reaction, with many graded as serious.[1][2]
Most Frequent Side Effects and Their Rates
These effects happened in 20% or more of patients:
- Neutropenia: 42% (often severe, grade 3-4 in 41%)
- Thrombocytopenia: 30%
- Anemia: 24%
- Peripheral neuropathy: 23% (mostly mild to moderate sensory)
- Fatigue: 21%
- Diarrhea: 20%
- Pneumonia: 13% (but infections overall hit 42%)[2][3]
Less common but notable: Febrile neutropenia (16%), infusion reactions (14%), and vomiting (18%). Most resolve with supportive care, but some like neuropathy can persist.[2]
What Counts as 'Common' in Cancer Drugs?
FDA labels classify adverse events as 'common' if they occur in ≥10-20% of patients. Polivy's profile fits this—hematologic toxicities (low blood counts) dominate due to its antibody-drug conjugate mechanism targeting CD79b and delivering chemotherapy intracellularly. Rates are similar to comparators like rituximab combos.[1][3]
Do Severe Side Effects Happen Often?
Yes, grade 3-4 (severe) events occurred in 72% of patients. Neutropenia led to treatment delays in 13% and discontinuation in 3%. Fatal events tied to infections or cytopenias affected 5%.[2] Dose adjustments or growth factors often manage these.
How Do Patients Experience Them Long-Term?
Peripheral neuropathy affects 40% by end of treatment, with 20% still symptomatic at 1 year post-treatment. Monitoring and early intervention reduce risks.[3] Real-world data aligns with trials, though supportive care improves tolerability.[1]
[1]: Polivy Prescribing Information (FDA)
[2]: GO29365 Trial (NEJM, 2019)
[3]: Drugs.com - Polivy Side Effects